Daraxonrasib For Pancreatic Cancer: What To Know
- A phase 3 interim analysis showed daraxonrasib achieved its primary endpoints with a median overall survival of 13.2 months vs. 6.7 months for standard chemotherapy for patients with refractory metastatic pancreatic ductal adenocarcinoma (PDAC).
- Daraxonrasib is being positioned as a broad RAS-directed therapy rather than a single-variant drug. Certainly, the results potentially expand the relevance of targeted therapy to “almost all” patients with pancreatic cancer, given that RAS mutations are detected in more than 90% of cases.
- “If the FDA approves the drug after reviewing the efficacy and safety data, the initial population would be patients with previously treated metastatic pancreatic cancer. That’s just the beginning,” Dr. Anna Berkenblit, Chief Scientific and Medical Officer at PanCAN, tells SurvivorNet Connect.
- Detailed peer-reviewed efficacy and safety data, including subgroup outcomes, response metrics, duration of response, and patient-reported outcomes, remain enormously important for implementation and are yet to come.
Though daraxonrasib hasn’t yet received Food and Drug Administration (FDA) approval, the RAS inhibitor has already ignited talks of major shifts in the treatment approach for patients with refractory metastatic pancreatic ductal adenocarcinoma (PDAC). Phase 3 data show the drug nearly doubled overall survival compared to chemotherapy.
Drug developer Revolution Medicines announced that in the pivotal RASolute 302 study, the drug achieved its primary endpoints with a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for investigator’s choice chemotherapy in previously treated metastatic PDAC.
“We’ve known for decades now that RAS is really important for many cancers, particularly pancreatic cancer, where over 90% of patients with pancreatic cancer have a RAS mutation,” Dr. Anna Berkenblit, Chief Scientific and Medical Officer at Pancreatic Cancer Action Network (PanCAN), tells SurvivorNet Connect. “For decades, RAS were considered undruggable because of how the protein looks. But they had figured out how to target it, how to drug it, and how to stop it from continuing to grow into cancers.”
For medical oncologists, the news means second-line treatment conversation could become materially different. The current phase 3 program specifically enrolled patients with metastatic PDAC after one prior line of therapy, comparing daraxonrasib against standard chemotherapy, placing the drug squarely in a setting where efficacy gains have historically been difficult to achieve.
Revolution Medicines has emphasized that the study included patients with a broad range of RAS variants, and the company’s stated mechanism is broader than a mutation-specific KRAS inhibitor.
What To Consider If Approval Follows
Daraxonrasib is being positioned as a broad RAS-directed therapy rather than a single-variant drug. Certainly, the results potentially expand the relevance of targeted therapy to “almost all” patients with pancreatic cancer, given that RAS mutations are detected in more than 90% of cases.
In practice, that would likely keep comprehensive molecular profiling highly relevant while reducing the sense that only a narrow molecular subset stands to benefit. That is an inference from the trial design and mechanism, not a regulatory claim.
“If you look at the entire population, the benefit is associated with a hazard ratio of 0.4, which means daraxonrasib reduces the risk of death by 60%,” Dr. Berkenblit adds.
Additionally, if the current data package supports approval, clinicians should expect rapid interest in treatment sequencing. Revolution Medicines has already started RASolute 303, a phase 3 trial evaluating daraxonrasib as monotherapy and in combination with gemcitabine/nab-paclitaxel compared to standard chemotherapy in previously untreated metastatic PDAC. The company has also stated that daraxonrasib is being evaluated in three phase 3 PDAC trials overall.
For clinicians, that means any eventual approval in the refractory metastatic setting would probably be only the first step in a broader repositioning of RAS inhibition across pancreatic cancer care.
“If the FDA approves the drug after reviewing the efficacy and safety data, the initial population would be patients with previously treated metastatic pancreatic cancer. That’s just the beginning,” Dr. Berkenblit explains.
Looking To The Future
Official communications so far remain appropriately high-level. Revolution Medicines says daraxonrasib was generally well-tolerated, with a manageable safety profile and no new safety signals in this first interim phase 3 analysis.
Another issue to watch is how the field interprets “practice changing” before full dataset disclosure. The interim analysis reports a striking survival advantage, but detailed peer-reviewed efficacy and safety data, including subgroup outcomes, response metrics, duration of response, and patient-reported outcomes, remain enormously important for implementation.
Revolution Medicines has stated that secondary endpoints in RASolute 302 include objective response rate, duration of response, and patient-reported quality of life, and PanCAN has specifically said it is looking forward to reviewing detailed results at ASCO. For clinicians, enthusiasm is justified, but integration into routine care will depend on the level of data granularity.
One of the most consequential questions after any approval would be patient selection beyond the label. The strongest official evidence right now is in previously treated metastatic PDAC, not in first-line metastatic disease, locally advanced disease, or resected disease. Yet the development program is already moving into those spaces. It’s reasonable to expect substantial interest in off-label discussion and trial referral.
